South Koreans rush to Japan for cheaper weight-loss drugs

South Korean consumers are taking advantage of a significant price gap between their home country and Japan, booking every available appointment at a Japanese telemedicine provider through mid-November. The rush comes after South Korea's government on Thursday approved regulations permitting citizens to bring weight-loss medications such as Mounjaro into the country when prescribed by foreign doctors.

Weights-loss drugs like Mounjaro, used to treat obesity and diabetes, cost substantially less in Japan compared to South Korea, making cross-border medical tourism an attractive option for cost-conscious consumers. The price differential has driven unprecedented demand for telemedicine services in Japan that cater to Korean patients seeking remote consultations and prescriptions.

The regulatory change in South Korea removes previous barriers that effectively prevented citizens from importing obesity treatments prescribed abroad. This policy shift opens new opportunities for medical tourism in the region, as patients increasingly seek cost-effective alternatives to expensive domestic healthcare services.

The phenomenon reflects broader trends across Asia, where healthcare cost disparities between neighboring countries drive cross-border medical consumption. As obesity and metabolic disease become growing health concerns in developed Asian economies, pricing policies and regulatory frameworks will likely play a significant role in shaping patient behavior and pharmaceutical access.